Guidelines for Biomarker Testing in Gastroenteropancreatic Neuroendocrine Neoplasms: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2013 Jun 11

PMID 23749327

Citations 5

Authors

R Garcia-Carbonero

F Vilardell

P Jimenez-Fonseca

R Gonzalez-Campora

E Gonzalez

M Cuatrecasas

J Capdevila

I Aranda

J Barriuso

X Matias-Guiu

Affiliations

Soon will be listed here.

Abstract

The annual incidence of neuroendocrine tumours in the Caucasian population ranges from 2.5 to 5 new cases per 100,000 inhabitants. Gastroenteropancreatic neuroendocrine tumours is a family of neoplasms widely variable in terms of anatomical location, hormone composition, clinical syndromes they cause and in their biological behaviour. This high complexity and clinical heterogeneity, together with the known difficulty of predicting their behaviour from their pathological features, are reflected in the many classifications that have been developed over the years in this field. This article reviews the main tissue and clinical biomarkers and makes recommendations for their use in medical practice. This document represents a consensus reached jointly by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

Citing Articles

Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.

Hong L, Wang Y, Zhang T, Zhang C, Wang L, Wang L Med Sci Monit. 2020; 26:e926635.

PMID: 33141811 PMC: 7648406. DOI: 10.12659/MSM.926635.

Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice.

Lamarca A, Clouston H, Barriuso J, McNamara M, Frizziero M, Mansoor W J Clin Med. 2019; 8(10).

PMID: 31590343 PMC: 6833016. DOI: 10.3390/jcm8101630.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).

Gonzalez-Flores E, Serrano R, Sevilla I, Viudez A, Barriuso J, Benavent M Clin Transl Oncol. 2018; 21(1):55-63.

PMID: 30535553 PMC: 6339660. DOI: 10.1007/s12094-018-1980-7.

Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Petersenn S, Koch C Rev Endocr Metab Disord. 2018; 18(4):373-378.

PMID: 29480376 DOI: 10.1007/s11154-018-9442-7.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.

Garcia-Carbonero R, Jimenez-Fonseca P, Teule A, Barriuso J, Sevilla I Clin Transl Oncol. 2014; 16(12):1025-34.

PMID: 25183048 PMC: 4239790. DOI: 10.1007/s12094-014-1214-6.

References

Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol A, Nilsson O . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2008; 90(2):162-6. DOI: 10.1159/000182196. View

Nobels F, Kwekkeboom D, Coopmans W, Schoenmakers C, Lindemans J, de Herder W . Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997; 82(8):2622-8. DOI: 10.1210/jcem.82.8.4145. View

Panarelli N, Yantiss R, Yeh M, Liu Y, Chen Y . Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol. 2012; 138(2):211-22. DOI: 10.1309/AJCPKSHXI3XEHW1J. View

Abgral R, Leboulleux S, Deandreis D, Auperin A, Lumbroso J, Dromain C . Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011; 96(3):665-71. DOI: 10.1210/jc.2010-2022. View

La Rosa S, Marando A, Furlan D, Sahnane N, Capella C . Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012; 36(4):601-11. DOI: 10.1097/PAS.0b013e318242e21c. View

Witzigmann H, Loracher C, Geissler F, Wagner T, Tannapfel A, Uhlmann D . Neuroendocrine tumours of the duodenum. Clinical aspects, pathomorphology and therapy. Langenbecks Arch Surg. 2002; 386(7):525-33. DOI: 10.1007/s00423-001-0260-z. View

Meric-Bernstam F, Akcakanat A, Chen H, Do K, Sangai T, Adkins F . PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012; 18(6):1777-89. PMC: 3307149. DOI: 10.1158/1078-0432.CCR-11-2123. View

Molina R, Alvarez E, Aniel-Quiroga A, Borque M, Candas B, Leon A . Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol. 2010; 32(1):13-22. DOI: 10.1007/s13277-010-0085-x. View

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

10.

Feldman J, ODorisio T . Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986; 81(6B):41-8. DOI: 10.1016/0002-9343(86)90583-8. View

11.

Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, Della Peruta M . Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2009; 28(2):245-55. PMC: 4288616. DOI: 10.1200/JCO.2008.21.5988. View

12.

Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra D . The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010; 456(6):595-7. DOI: 10.1007/s00428-010-0924-6. View

13.

Yao J, Pavel M, Phan A, Kulke M, Hoosen S, St Peter J . Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011; 96(12):3741-9. DOI: 10.1210/jc.2011-0666. View

14.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

15.

Kulke M, Hornick J, Frauenhoffer C, Hooshmand S, Ryan D, Enzinger P . O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009; 15(1):338-45. PMC: 3100724. DOI: 10.1158/1078-0432.CCR-08-1476. View

16.

Engel K, Moore H . Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2011; 135(5):537-43. DOI: 10.5858/2010-0702-RAIR.1. View

17.

OToole D, Couvelard A, Rebours V, Zappa M, Hentic O, Hammel P . Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010; 17(4):847-56. DOI: 10.1677/ERC-09-0204. View

18.

Oberg K, Eriksson B . Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab. 2005; 19(2):265-76. DOI: 10.1016/j.beem.2004.11.016. View

19.

Service F . Hypoglycemic disorders. N Engl J Med. 1995; 332(17):1144-52. DOI: 10.1056/NEJM199504273321707. View

20.

Jiao Y, Shi C, Edil B, de Wilde R, Klimstra D, Maitra A . DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331(6021):1199-203. PMC: 3144496. DOI: 10.1126/science.1200609. View